Mezzion Pharma Co.Ltd
Mezzion Pharma Co.,Ltd. engages in the development, licensing, and commercialization of drugs for the treatment of vascular diseases. It is developing Udenafil, a PDE5 inhibitor to treat erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, overactive bladder, hepatic portal hypertension, and chronic obstructive pulmonary diseases. The company was formerly known as … Read more
Mezzion Pharma Co.Ltd (140410) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.076x
Based on the latest financial reports, Mezzion Pharma Co.Ltd (140410) has a cash flow conversion efficiency ratio of -0.076x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.83 Billion) by net assets (₩37.35 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mezzion Pharma Co.Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Mezzion Pharma Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Mezzion Pharma Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mezzion Pharma Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chongqing Fuling Zhacai Group Co Ltd
SHE:002507
|
0.042x |
|
NGL Energy Partners LP
NYSE:NGL
|
0.309x |
|
Beijing Venustech Inc
SHE:002439
|
0.004x |
|
Simply Good Foods Co
NASDAQ:SMPL
|
0.029x |
|
Ora Banda Mining Ltd
AU:OBM
|
0.472x |
|
Shenzhen Dynanonic Co Ltd
SHE:300769
|
-0.043x |
|
Playa Hotels & Resorts BV
NASDAQ:PLYA
|
0.147x |
|
HBIS Co Ltd
SHE:000709
|
0.053x |
Annual Cash Flow Conversion Efficiency for Mezzion Pharma Co.Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Mezzion Pharma Co.Ltd from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩46.06 Billion | ₩-18.49 Billion | -0.401x | -123.74% |
| 2023-12-31 | ₩61.44 Billion | ₩-11.02 Billion | -0.179x | +61.01% |
| 2022-12-31 | ₩26.24 Billion | ₩-12.07 Billion | -0.460x | -91.72% |
| 2021-12-31 | ₩62.79 Billion | ₩-15.07 Billion | -0.240x | -84.84% |
| 2020-12-31 | ₩56.81 Billion | ₩-7.38 Billion | -0.130x | +73.36% |
| 2019-12-31 | ₩42.83 Billion | ₩-20.88 Billion | -0.488x | -28.63% |
| 2018-12-31 | ₩57.32 Billion | ₩-21.72 Billion | -0.379x | -52.50% |
| 2017-12-31 | ₩53.17 Billion | ₩-13.21 Billion | -0.249x | -115.96% |
| 2016-12-31 | ₩52.81 Billion | ₩-6.08 Billion | -0.115x | -506.08% |
| 2015-12-31 | ₩62.54 Billion | ₩1.77 Billion | 0.028x | -42.77% |
| 2012-12-31 | ₩63.34 Billion | ₩3.14 Billion | 0.050x | -- |